Status:
COMPLETED
DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS
Lead Sponsor:
AB Biotek
Conditions:
Insomnia
Insomnia Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can l...
Eligibility Criteria
Inclusion
- Older than 18 years old
- With one or more symptoms of insomnia
- Explicit acceptance to participate to the study through informed consent
Exclusion
- Insomnia symptoms that could be justified by the existance of another sleep pathology (e.g., narcolepsy)
Key Trial Info
Start Date :
May 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06488027
Start Date
May 5 2023
End Date
November 27 2023
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AdSalutem Sleep Institute
Barcelona, Barcelona, Spain, 08008